ADMA Biologics Inc
NASDAQ:ADMA
Intrinsic Value
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. [ Read More ]
The intrinsic value of one ADMA stock under the Base Case scenario is 5.01 USD. Compared to the current market price of 6.6 USD, ADMA Biologics Inc is Overvalued by 24%.
Valuation Backtest
ADMA Biologics Inc
Run backtest to discover the historical profit from buying and selling ADMA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of ADMA Biologics Inc's business.
What risks and challenges
does ADMA Biologics Inc face in the near future?
Summarize the latest earnings report
of ADMA Biologics Inc.
Provide P/E
for ADMA Biologics Inc and its competitors.
Balance Sheet Decomposition
ADMA Biologics Inc
Current Assets | 257m |
Cash & Short-Term Investments | 51.4m |
Receivables | 27.4m |
Other Current Assets | 178.2m |
Non-Current Assets | 72.2m |
PP&E | 63.5m |
Intangibles | 4m |
Other Non-Current Assets | 4.7m |
Current Liabilities | 49.8m |
Accounts Payable | 15.7m |
Accrued Liabilities | 31.1m |
Other Current Liabilities | 3.1m |
Non-Current Liabilities | 144.2m |
Long-Term Debt | 130.6m |
Other Non-Current Liabilities | 13.6m |
Earnings Waterfall
ADMA Biologics Inc
Revenue
|
258.2m
USD
|
Cost of Revenue
|
-169.3m
USD
|
Gross Profit
|
88.9m
USD
|
Operating Expenses
|
-67.3m
USD
|
Operating Income
|
21.6m
USD
|
Other Expenses
|
-49.9m
USD
|
Net Income
|
-28.2m
USD
|
Free Cash Flow Analysis
ADMA Biologics Inc
What is Free Cash Flow?
ADMA Profitability Score
Profitability Due Diligence
ADMA Biologics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
ADMA Biologics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
ADMA Solvency Score
Solvency Due Diligence
ADMA Biologics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
ADMA Biologics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADMA Price Targets Summary
ADMA Biologics Inc
According to Wall Street analysts, the average 1-year price target for ADMA is 8.16 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.
Ownership
ADMA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ADMA Price
ADMA Biologics Inc
Average Annual Return | 22.61% |
Standard Deviation of Annual Returns | 96.1% |
Max Drawdown | -80% |
Market Capitalization | 1.5B USD |
Shares Outstanding | 228 220 000 |
Percentage of Shares Shorted | 3.09% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 527 full-time employees. The company went IPO on 2013-10-17. The firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.
Contact
IPO
Employees
Officers
The intrinsic value of one ADMA stock under the Base Case scenario is 5.01 USD.
Compared to the current market price of 6.6 USD, ADMA Biologics Inc is Overvalued by 24%.